title: Dalbavancin.
abstract: Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The October 2014 monograph topics are ortitavancin diphosphate, insulin human inhalation powder, empaglifozin, efinaconazole topical solution, 10%, and tavaborole topical solution, 5%. The DUE/MUE is on oritavancin diphosphate.
authors.affiliation: Founder and Contributing Editor, The Formulary , Washington State University , Spokane, Washington.
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Cada
authors.affiliation: Drug Information Resident, Drug Information Center, Washington State University , Spokane, Washington.
authors.forename: Kyle
authors.initials: K
authors.lastname: Ingram
authors.affiliation: Drug Information Intern, Drug Information Center, Washington State University , PO Box 1495, Spokane, Washington 99210-1495 . ; Director, Drug Information Center, and Professor of Pharmacy Practice, College of Pharmacy, Washington State University Spokane , PO Box 1495, Spokane, Washington 99210-1495 . The authors indicate no relationships that could be perceived as a conflict of interest.
authors.forename: Danial E
authors.initials: DE
authors.lastname: Baker